TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dyslexia, Motor Control and Proprioception

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for all children~* Child with a French social security~* School child~* Native French speaker~* right-handed~* Normal or corrected vision~* Without neurological or psychiatric histories~* Agree to participate in the study in agreement with parental rights representatives~For the dyslexic group :~* pluridisciplinary diagnostic~* never consulted for proprioception before~* without any other leaning disorders like dysphasia~* attention deficit hyperactivity disorder (ADHD) or developmental coordination disorder (DCD)~For the control group :~* regular school attendance~* never consulted for learning disabilities~* No learning disorders known for their parents or siblings.~Exclusion criteria for all children~* genetic disorder~* neurological or psychiatric history~* Delayed psychomotor development~* Reeducation or current treatment interfering with the evaluation

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Dyslexic and non dyslexic Children (Type: EXPERIMENTAL): Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proof of Concept BeatPark

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's Disease confirmed by the United Kingdom Parkinson's Disease Society Brain Bank's criteria (Gibb and Lees, 1988; Hughes et al., 1992)~* Gait disorder confirmed by a neurologist~* Ability to walk more than 30 minutes without any device as a stick or a walker~* Stability of the dopaminergic treatment~Exclusion Criteria:~* Pregnancy~* Hearing problems~* Other neurological disease affecting gait other than PD~* Other gait disorder whetever the etiology (orthopedic, rheumatologic....)~* Uncompensated heart or respiratory failure excluding possibility of intensiv rehabilitation.~* Arguments for atypical parkinsonism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Patients with parkinson's disease (Type: EXPERIMENTAL): Patients with parkinson's disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with a diagnosis of: Severe combined immunodeficiency disease~This includes patients whose SCID is characterized by gene specific mutations as well as patients with clinically severe combined immunodeficiency without a defined genetic cause in which the diagnosis will be determined by a combination of clinical course with lymphocyte quantification and function assays.~OR~Severe primary immunodeficiency disorder, including undefined T cell deficiency disorder, Wiskott-Aldrich syndrome, and other severe immunodeficiencies for which satisfactory conventional therapy does not exist.~* Availability of an HLA mismatched (up to one haplotype) family member or an HLA matched or mismatched (up to one antigen) unrelated donor.~* Creatinine \< 2.5 x normal for age.~* Life expectancy greater than 6 weeks~* Lansky/Karnofsky greater than or equal to 70%~Exclusion Criteria:~* Patients with an HLA matched related donor~* Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction less than 25%)~* Patients with known allergy to rat serum products~* Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation~* HIV positive~* Pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants With SCID or Primary Immunodeficiency Disorder (Type: EXPERIMENTAL): all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Spinal cord injury group:~* Males or females with chronic SCI (i.e. at least 6 months after the initial injury)~* International Standard for Neurological Classification of SCI (ISNCSCI) A-D~* Neurological level of injury C6 or below~* 18-55 years old~* Proficient in English~* Able to detect middle cerebral artery blood velocity (MCAv) and/or posterior cerebral artery blood velocity (PCAv) signals through TCD~Non-injured controls:~* Males or females without SCI~* 18-55 years old~* Proficient in English~* Able to detect MCAv and/or PCAv signals through TCD~Exclusion Criteria:~* Cardiovascular, pulmonary or respiratory diseases, or diabetes mellitus, any other diseases/disorders affecting cardiac autonomic nervous system, such as glaucoma and attention deficit hyperactivity disorder (ADHD)~* Color Blindness~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CON (Type: ACTIVE_COMPARATOR): Age-and sex-matched healthy controls with exercise intervention
- SCI (Type: EXPERIMENTAL): Individuals with spinal cord injury

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients under their first or second cycle of a synchronous donation~* to have a minimum of 5 available embryos to transfer~* patients who accept transfers of frozen-thawed embryos~Exclusion Criteria:~* medical indications to transfer only one embryo (Turner Syndrome, uterine surgical history, uterine myomas,...)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- SET (Type: EXPERIMENTAL): Single embryo transfer
- DET (Type: ACTIVE_COMPARATOR): Double embryo transfer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brain Vital Signs M-Score: Point-of-care Monitoring for Motor Recovery After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age requirements:~  * Younger adult control participants (19-40 years old)~ * Older adult control participants (41-80 years old)~ * Individuals with stroke (19-80 years old)~* Capacity to follow single stage commands~* Stroke specific inclusion criteria~  * Upper-limb disability as a result of a stroke (\>1 month ago)~Exclusion Criteria:~* Cognitive difficulties that undermine ability to give informed consent (Montreal Cognitive Assessment (MoCA) score below 23).~* Severe paralysis such that the participant cannot perform simple movements (such as finger tapping, clicking a mouse, etc.)~* History of head trauma, a major psychiatric diagnosis, neurodegenerative disorder or substance abuse

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Individuals with stroke (Type: None): Participants in sub-acute and chronic phases post-stroke (\>1 month post-stroke) will be recruited for participation in this study.
- Adult control participants (Type: None): Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HIV, Computerized Depression Therapy & Cognition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in the cohort study Understanding and Optimizing Brain Health in HIV Now with at least one remaining visit~* Able to communicate (understand and read) in English~* Depression subscale of the HADS (HADS-D) ≥ 8~* Presence of self-reported cognitive difficulties (PDQ) \>40~* Score on the B-CAM \> 14~* Willing to undergo 9 sessions of cCBT as per instructions and to have weekly contact with a research coordinator from the central site (by email or phone)~* Access to the internet~Exclusion Criteria:~• Current use of street drugs (excluding marijuana)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cCBT intervention (Type: EXPERIMENTAL): Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed and dated by the patient and the caregiver.~* Patients having participated in AFFiRiS 005A and received ≥1 vaccination with AFFITOPE AD03~* Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits and being available for the telephone phone calls~Exclusion Criteria:~* Patients having received no vaccination with AFFITOPE AD03~* History of questionable compliance to visit schedule; patients not expected to complete the clinical trial

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AFFITOPE AD03 with adjuvant (Type: None): None
- AFFITOPE AD03 without adjuvant (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Early Enteral Nutrition in Severe Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe stroke occurred in 7 days.~* GCS ≤12 or NIHSS≥11.~* Any cases of profiles #3 through 5 in Water Swallowing Test or with disorder of consciousness.~* Plan to receive enteral feeding for at least 7 days.~* Informed consent.~Exclusion Criteria:~* Gastrointestinal diseases before stroke, such as gastrointestinal resection, malabsorption,and irritable bowel syndrome.~* Brain death.~* Complicated with the disease which only have life expectancy \< 6 months in over 50% patients.~* After cardiac arrest.~* Received parenteral nutrition support.~* Pregnant woman.~* Concurrent severe hepatic or renal dysfunction。~* Unstable hemodynamics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full enteral feeding (Type: ACTIVE_COMPARATOR): The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
- Modified full enteral feeding (Type: EXPERIMENTAL): Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.
- Permissive underfeeding (Type: EXPERIMENTAL): The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Methadone Versus Morphine for Cancer-Related Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a telephone~* Age: patient must be 18 years or older and less than 70 years of age~* Life expectancy of 3 months or greater~* No prior use of step-3 opioids (step 2 opioids are allowed)~* Provision of informed consent~* Score of 26 or greater on Mini-Mental Status Exam (MMSE) (to be done by investigator if there is question about mental status)~* Nonmalignant pain will be excluded; however, if the patient has both malignant and nonmalignant pain, entry into the trial will be determined by the predominant site of pain~* Moderate to severe cancer related pain that requires the use of step-3 opioids~* Normal renal function~* There will be no exclusionary criteria based on Karnofsky score~* Must live no more than 1 hour away from clinic~* Patient must have pain severity of 5-7/10 on a 0-10 pain scale~Exclusion Criteria:~* Nursing home patients~* Obvious cognitive dysfunction~* Intractable nausea or vomiting~* A true allergy or intolerance to opioids~* Unstable renal function~* Undergoing therapeutic procedures likely to influence pain during the study period~* Gastrointestinal pathology or surgery that influences absorption of morphine or methadone~* Must not have had treatment with radiotherapy, chemotherapy or radionuclides in the last 30 days~* History of drug seeking behavior~* Respiratory compromise~* Treatment with bisphosphonates within the last month~* Use of MAO inhibitors~* Drugs that interfere with CYP34A or CYP2D6~* Drugs that interfere with morphine metabolism~* Retroviral therapies~* Active radiation or antineoplastic therapies~* Hepatic dysfunction~* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study~* Study will exclude women who are pregnant and/or nursing~* Women who are of child bearing potential must have a negative urine pregnancy test~* Patients with a recent substance abuse history will be excluded~* Patients with major depression will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Methadone (Type: ACTIVE_COMPARATOR): Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
- Morphine (Type: ACTIVE_COMPARATOR): Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing one- or two-level posterior lumbar fusion with or without decompression at University of Vermont Medical Center~* 18-75 years of age~* Signed consent form~Exclusion Criteria:~* Allergy to lidocaine~* Contraindication to lidocaine, such as substantial hepatic impairment (alanine aminotransferase or aspartate transaminase more than twice normal), renal impairment (serum creatinine \>2 mg/dl)~* Seizures or a history of seizure disorder~* Congestive heart failure~* Arrythmias~* Chronic opioid use \>45 mg morphine equivalent per day~* Trauma patients~* Inter-body fusions~* Severe psychiatric comorbidities~* Planned epidural anesthesia or analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous Lidocaine Infusion (Type: EXPERIMENTAL): Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
- Placebo Infusion (Type: PLACEBO_COMPARATOR): Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if they meet the following criteria:~* male or female,~* age 25-70 years,~* BMI 26-65,~* type 2 diabetic,~* weight stable for 3 months,~* status post laparoscopic adjustable gastric banding (LAGB) for at least 1 year,~* hemoglobin a1c 7-10%;~* on any diabetic regimen including insulin except for thiazolidinedione use in the past 6 months.~Exclusion Criteria:~Subjects will be excluded if they meet any of the following criteria:~* prior history of pancreatitis,~* prior history of gastroparesis,~* glomerular filtration rate (GFR) \< 50,~* history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer,~* history of cholelithiasis,~* history of hyperoxaluria or calcium oxalate nephrolithiasis,~* abnormal AST,~* ALT elevation,~* current or past history of liver disease,~* history of Roux-en-y gastric bypass or gastric sleeve or any other bariatric procedure other than LAGB,~* type 1 diabetes,~* any gastrointestinal disease causing malabsorption (including but not limited to inflammatory bowel disease, celiac sprue),~* prior history of Orlistat or incretin therapy use in past 3 months,~* unwilling or unable to complete scheduled testing,~* thiazolidinedione use within past 6 months,~* any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study.~Patients who have had organ transplantation are on chronic anticoagulation, pregnant or have A1C values \> 10% will also be excluded.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide only (Type: ACTIVE_COMPARATOR): None
- Orlistat only (Type: ACTIVE_COMPARATOR): None
- Liraglutide + Orlistat (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues